Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197183
Max Phase: Preclinical
Molecular Formula: C68H77BF2N10O9S
Molecular Weight: 1259.30
Associated Items:
ID: ALA5197183
Max Phase: Preclinical
Molecular Formula: C68H77BF2N10O9S
Molecular Weight: 1259.30
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)NCCC(=O)N[C@@H](CCCCNC(=O)COc1ccc(/C=C/C2=[N+]3C(=Cc4ccc(-c5cccs5)n4[B-]3(F)F)C=C2)cc1)C(N)=O
Standard InChI: InChI=1S/C68H77BF2N10O9S/c1-46(75-67(87)47(2)76-68(88)58(43-50-16-7-4-8-17-50)78-63(83)35-40-79-38-33-56(34-39-79)90-60-20-10-9-18-51(60)42-49-14-5-3-6-15-49)66(86)74-37-32-62(82)77-57(65(72)85)19-11-12-36-73-64(84)45-89-55-29-23-48(24-30-55)22-25-52-26-27-53-44-54-28-31-59(61-21-13-41-91-61)81(54)69(70,71)80(52)53/h3-10,13-18,20-31,41,44,46-47,56-58H,11-12,19,32-40,42-43,45H2,1-2H3,(H2,72,85)(H,73,84)(H,74,86)(H,75,87)(H,76,88)(H,77,82)(H,78,83)/b25-22+/t46-,47-,57-,58-/m0/s1
Standard InChI Key: QUFCRYDWDBOHAG-WTRYCTIGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1259.30 | Molecular Weight (Monoisotopic): 1258.5657 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):